Indonesia vs Vanuatu: Statin use vs. average non-HDL cholesterol levels
Indonesia
3.6
in 2018
Vanuatu
3.6
in 2018
Indonesia rank
30th
Vanuatu rank
30th
Statin use vs. average non-HDL cholesterol levels over time
- Indonesia
- Vanuatu
How they compare
Indonesia currently reports 3.6 against 3.6 in Vanuatu, a difference of 0.
Across all 39 years both countries report, Vanuatu has been ahead every year.
Indonesia ranks 30th and Vanuatu ranks 30th of 191 countries.
Vanuatu has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Indonesia | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.9 | 3.32 | 0.42 | Vanuatu |
| 1990s | 2.93 | 3.47 | 0.54 | Vanuatu |
| 2000s | 3.15 | 3.52 | 0.37 | Vanuatu |
| 2010s | 3.5 | 3.6 | 0.1 | Vanuatu |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Indonesia or Vanuatu?
- Indonesia, at 3.6 against 3.6 in Vanuatu as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Indonesia and Vanuatu?
- 0, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Vanuatu?
- 39 years are reported by both, from 1980 to 2018.
- How do Indonesia and Vanuatu rank globally for statin use vs. average non-hdl cholesterol levels?
- Indonesia ranks 30th and Vanuatu ranks 30th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.